iShares MSCI Australia ETF vs Cassava Sciences Inc — how do they compare? iShares MSCI Australia ETF trades at $28.59, while Cassava Sciences Inc trades at $1.06 (market cap $53.14M). The key difference: iShares MSCI Australia ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| EWA | FLNA | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $30.26 | $4.64 |
52-Week Low | $24.95 | $1.09 |
Market Cap | — | $53.14M |
Enterprise Value | — | -$33.43M |
Signals from Pluang's Aura AI — not financial advice
EWA trades at $28.625, down 0.3% with a bullish technical signal from moving averages. The stock shows neutral oscillator readings with RSI at 72.02 suggesting potential overbought conditions. Recent news highlights Australia's economic developments including fuel excise relief and tax reforms that may impact investor sentiment toward Australian-focused assets.
The outlook remains cautiously optimistic given the bullish technical setup, though limited fundamental data availability requires careful monitoring. Key risks include Australian economic sensitivity and market volatility from geopolitical tensions. Investors should await updated financial metrics for comprehensive fundamental assessment.
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Trailing returns across standard periods
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →